LENZ Therapeutics Reports Q2 2026 Financial Results with $5.5M Revenue and $31.9M Net Loss

LENZ Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $5.5 million, a notable increase from $5.0 million in the same period of 2025. This growth was primarily driven by product sales of $1.7 million from its recently launched VIZZ® (aceclidine ophthalmic solution) 1.44%, which became commercially available in August 2025. The company also recognized $3.75 million in license revenue, although this figure represents a 25% decline from the $5 million recorded in the prior year, attributed to the absence of new milestone payments during the quarter.

In terms of expenses, LENZ's operating costs surged to $39.7 million for the quarter, up from $21.9 million in the previous year, marking an increase of 81%. The rise in expenses was largely due to a significant escalation in selling, general, and administrative costs, which reached $39.4 million, compared to $12.8 million in the prior year. This increase reflects the company's investment in marketing and sales infrastructure to support the commercialization of VIZZ. Research and development expenses dropped to zero, down from $9.1 million, as the company transitioned costs related to VIZZ's commercialization into general administrative expenses following FDA approval.

As of June 30, 2026, LENZ reported an accumulated deficit of $300.5 million, with cash, cash equivalents, and marketable securities totaling $220 million. The company has incurred net losses consistently since its inception, with a net loss of $31.9 million for the second quarter of 2026, compared to a loss of $14.9 million in the same quarter of 2025. The increase in losses is attributed to the company's ongoing investment in its commercial strategy and infrastructure.

Operationally, LENZ has made significant strides in expanding its market presence. The company has initiated a telehealth platform for VIZZ, enhancing patient access through online evaluations and home delivery services. Additionally, LENZ has entered into various licensing agreements, including a recent deal with Arrotex Pharmaceuticals for commercialization in Australia and New Zealand, and an agreement with Everest Medicines for rights in Greater China. These strategic partnerships are expected to bolster LENZ's international market reach and revenue potential.

Looking ahead, LENZ anticipates continued investment in its commercialization efforts for VIZZ, which is projected to tap into a U.S. market opportunity exceeding $3 billion. The company acknowledges the need for additional financing to support its growth and operational needs, particularly as it navigates the early stages of product commercialization.